Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience

Background Combination of dabrafenib–trametinib is one of the standard treatments in patients with BRAF-mutated advanced malignant melanoma (MM). Real-world data on the usage of this combination is scarce, especially from India. Here, we are reporting our early experience with the usage of this comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Ganguly, Sandip, Ghosh, Joydeep, Mishra, Deepak, Biswas, Gautam, Dabkara, Deepak, Roy, Somanth, Biswas, Bivas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Private Ltd 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687866/
https://www.ncbi.nlm.nih.gov/pubmed/34938683
http://dx.doi.org/10.1055/s-0041-1736032